Valeant Pharmaceuticals (NYSE:VRX)‘s stock had its “positive” rating reiterated by analysts at Aegis in a research report issued to clients and investors on Monday, American Banking & Market News reports.
A number of other firms have also recently commented on VRX. Analysts at Zacks upgraded shares of Valeant Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, October 8th. They now have a $112.40 price target on the stock. Separately, analysts at CRT Capital raised their price target on shares of Valeant Pharmaceuticals from $110.00 to $130.00 in a research note to investors on Monday, October 7th. They now have a “buy” rating on the stock. Finally, analysts at BMO Capital Markets set a $123.00 price target on shares of Valeant Pharmaceuticals in a research note to investors on Wednesday, October 2nd. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $112.67.
Shares of Valeant Pharmaceuticals (NYSE:VRX) traded down 1.42% on Monday, hitting $110.97. The stock had a trading volume of 288,277 shares. Valeant Pharmaceuticals has a 52 week low of $50.74 and a 52 week high of $105.40. The stock has a 50-day moving average of $98.87 and a 200-day moving average of $84.03. The company’s market cap is $37.011 billion.
Valeant Pharmaceuticals (NYSE:VRX) last announced its earnings results on Wednesday, August 7th. The company reported $1.34 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.28 by $0.06. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $820.09 million. During the same quarter last year, the company posted $1.01 earnings per share. Valeant Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year. Analysts expect that Valeant Pharmaceuticals will post $6.14 EPS for the current fiscal year.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.